Cyrus A. Chowdhury
Managing Director & CEO
Mr. Chowdhury's career has focused on global market access issues across six continents, split evenly between emerging markets (BRIC-MT and through the top 73 emerging markets) and developed markets (EU-5, Japan, Australia and Canada). His achievements include successful assignments in pharmaceutical and medical technology price integrity, payer partnerships, innovative access schemes, patient access programmes, customer value approach, and portfolio-level global market access strategies. While with Genzyme, he developed the company's first parallel trade pricing defense strategy. While with Cambridge Pharma Consultancy (now part of IMS), Mr. Chowdhury played an integral role in launching the firm's Greater China market access consulting practice, spending much of his time focusing on pan-Asian issues. Additionally, Mr. Chowdhury served as a research specialist with the London School of Economics, WHO and European Observatory on Health for Central and Eastern Europe. Prior to founding CBPartners, Mr. Chowdhury founded and led the Global Market Access practice at ISA.
Mr. Chowdhury holds an Masters in International Health Policy from the London School of Economics, and a Bachelors in Neuroscience from Boston University.
WHO Stands to Benefit the Most from the Biosimilars Prequalification Programme?
22 November 2017
STRIMVELIS™ – The Proof Is In The Messaging
6 November 2017
Reframing the Opportunity: PDx Hope for Breast Cancer
16 October 2017
Rome Wasn’t Built in a Day Either: GRC Back Again with New Pricing and Reimbursement Policy Reforms
4 October 2017
Does the Fate of MS Pricing Lie in the Hands of Politicians or Manufacturers?
17 September 2017
The New AIFA Algorithm For Assessing ‘Innovativeness’ Of New Products In Italy: So What?
18 August 2017
ESRX’s New INSIDERX Strategy – PART II: Sure Savings or Just a Show?
12 July 2017
ISPOR International 2017 – Times That Try Souls
7 July 2017
Price Transparency – Let the Light Shine
12 June 2017
ESRX’s New INSIDERX Strategy – PART I: Cure for the Uninsured?
6 June 2017